Hops-r01 phase ii trial evaluating neoadjuvant s-1 therapy for resectable pancreatic adenocarcinoma

HIGHLIGHTS

• who: Toru Nakamura from the DepartmentHokkaido University have published the paper: HOPS-R01 phase II trial evaluating neoadjuvant S-1 therapy for resectable pancreatic adenocarcinoma, in the Journal: Scientific Reports Scientific Reports
• what: This trial showed that the 2-year PFS rate was 58.1% among 31 patients who completed Nac before receiving R0/ R1 resection (per-protocol). In fact, this study subpopulation that met the JASPAC01 trial criteria showed relatively better survival (Supplemental Fig Se2).

SUMMARY

A total of 80 patients were diagnosed with R-PDAC by central review of . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or E-mail:

If you don't have an account, you can create one here.